CO2021009078A2 - Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) - Google Patents
Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)Info
- Publication number
- CO2021009078A2 CO2021009078A2 CONC2021/0009078A CO2021009078A CO2021009078A2 CO 2021009078 A2 CO2021009078 A2 CO 2021009078A2 CO 2021009078 A CO2021009078 A CO 2021009078A CO 2021009078 A2 CO2021009078 A2 CO 2021009078A2
- Authority
- CO
- Colombia
- Prior art keywords
- usp1
- substituted
- ubiquitin
- inhibitors
- specific processing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente descripción proporciona compuestos que tienen la Fórmula I: I y las sales y solvatos farmacéuticamente aceptables de estos, donde X1, X2, X11, X12, R1, R3, R5, R5', R6 y R7 se definen como se indica en la memoria descriptiva. La presente descripción también hace referencia al uso de compuestos de Fórmula I para inhibir una proteína USP1 y/o para tratar un trastorno que responde a la inhibición de proteínas USP1 y la actividad de USP1. Los compuestos de la presente descripción son especialmente útiles para el tratamiento del cáncer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783014P | 2018-12-20 | 2018-12-20 | |
US201962799423P | 2019-01-31 | 2019-01-31 | |
US201962857986P | 2019-06-06 | 2019-06-06 | |
US201962868616P | 2019-06-28 | 2019-06-28 | |
US201962946263P | 2019-12-10 | 2019-12-10 | |
PCT/US2019/067521 WO2020132269A1 (en) | 2018-12-20 | 2019-12-19 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021009078A2 true CO2021009078A2 (es) | 2021-10-29 |
Family
ID=71100912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0009078A CO2021009078A2 (es) | 2018-12-20 | 2021-07-12 | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) |
Country Status (14)
Country | Link |
---|---|
US (2) | US11485736B2 (es) |
EP (1) | EP3897652A4 (es) |
JP (1) | JP2022511515A (es) |
KR (1) | KR20210105887A (es) |
CN (1) | CN113164485A (es) |
AU (1) | AU2019405925A1 (es) |
BR (1) | BR112021010715A2 (es) |
CA (1) | CA3122108A1 (es) |
CL (1) | CL2021001575A1 (es) |
CO (1) | CO2021009078A2 (es) |
IL (1) | IL284050A (es) |
MX (1) | MX2021007179A (es) |
SG (1) | SG11202106232TA (es) |
WO (1) | WO2020132269A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021007179A (es) | 2018-12-20 | 2021-09-28 | Ksq Therapeutics Inc | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). |
WO2021146378A1 (en) * | 2020-01-15 | 2021-07-22 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
KR20220140732A (ko) * | 2020-02-14 | 2022-10-18 | 케이에스큐 세러퓨틱스 인코포레이티드 | 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물 |
EP4161494A1 (en) * | 2020-06-02 | 2023-04-12 | KSQ Therapeutics, Inc. | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
TW202233621A (zh) * | 2020-10-30 | 2022-09-01 | 美商Ksq治療公司 | 經取代吡唑并嘧啶之固態形式及其用途 |
WO2022174184A1 (en) * | 2021-02-15 | 2022-08-18 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
WO2022197892A1 (en) * | 2021-03-17 | 2022-09-22 | Tango Therapeutics, Inc. | Purine derivatives as anticancer agents |
CA3214040A1 (en) * | 2021-04-07 | 2022-10-13 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
KR20240004634A (ko) * | 2021-05-03 | 2024-01-11 | 산동 수안주 파마 코포레이션 리미티드 | 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도 |
CN117412973A (zh) * | 2021-05-31 | 2024-01-16 | 上海瑛派药业有限公司 | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 |
GB202114863D0 (en) | 2021-10-18 | 2021-12-01 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
WO2023066299A1 (en) * | 2021-10-19 | 2023-04-27 | Impact Therapeutics (Shanghai) , Inc | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
CN114031556B (zh) * | 2021-11-08 | 2023-03-31 | 温州大学 | 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法 |
CA3235765A1 (en) | 2021-11-12 | 2023-05-19 | Jianping Wu | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
AU2022387669A1 (en) * | 2021-11-12 | 2024-05-16 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
CN114181237B (zh) * | 2021-12-01 | 2024-02-23 | 上海凌凯医药科技有限公司 | 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法 |
TW202328074A (zh) * | 2021-12-09 | 2023-07-16 | 美商Ksq治療公司 | 製備取代之吡唑并嘧啶之方法 |
WO2023143424A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种氮杂并环衍生物及其在医药上的应用 |
WO2023148643A1 (en) * | 2022-02-03 | 2023-08-10 | Aurigene Oncology Limited | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
WO2023155866A1 (zh) * | 2022-02-18 | 2023-08-24 | 四川海思科制药有限公司 | 一种吡唑并吡啶衍生物及其在医药上的应用 |
WO2023196955A1 (en) * | 2022-04-08 | 2023-10-12 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agents |
WO2023208130A1 (zh) * | 2022-04-29 | 2023-11-02 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
WO2023250084A1 (en) * | 2022-06-23 | 2023-12-28 | Forma Therapeutics, Inc. | Usp1 inhibitors and uses thereof |
WO2024006879A1 (en) * | 2022-06-29 | 2024-01-04 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
WO2024032647A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
WO2024041634A1 (zh) * | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | 三环类化合物及其应用 |
WO2024046471A1 (zh) * | 2022-09-02 | 2024-03-07 | 上海齐鲁制药研究中心有限公司 | Usp1抑制剂 |
WO2024051795A1 (zh) * | 2022-09-09 | 2024-03-14 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物 |
WO2024061213A1 (zh) * | 2022-09-20 | 2024-03-28 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 |
WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
WO2024094170A1 (zh) * | 2022-11-04 | 2024-05-10 | 深圳晶泰科技有限公司 | 泛素特异性蛋白酶1的抑制剂及其应用 |
CN116768906B (zh) * | 2023-05-29 | 2024-04-09 | 遵义医科大学珠海校区 | 一种三并环化合物及其制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
JP2763958B2 (ja) | 1990-06-11 | 1998-06-11 | ネクスター ファーマスーティカルズ,インコーポレイテッド | 核酸リガンド |
AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
WO1996023899A1 (en) | 1995-02-01 | 1996-08-08 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
CA2267139A1 (en) | 1996-10-08 | 1998-04-16 | Ton Logtenberg | Methods and means for selecting peptides and proteins having specific affinity for a target |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
WO2006068760A2 (en) * | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
US7754463B2 (en) | 2006-06-20 | 2010-07-13 | Dana-Farber Cancer Institute | Inhibitors of USP1 Deubiquitinating Enzyme Complex |
US20090062196A1 (en) | 2006-10-20 | 2009-03-05 | D Andrea Alan | Compositions and methods of treating cancer |
US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
KR101701109B1 (ko) * | 2007-10-05 | 2017-02-13 | 베라스템, 인코포레이티드 | 피리미딘 치환된 퓨린 유도체 |
US8598184B2 (en) * | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
WO2009157196A1 (ja) * | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | アミド化合物 |
GB0917934D0 (en) * | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
KR101766194B1 (ko) * | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물 |
AU2016356694B2 (en) * | 2015-11-20 | 2021-07-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
MX2021007179A (es) | 2018-12-20 | 2021-09-28 | Ksq Therapeutics Inc | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). |
WO2022174184A1 (en) | 2021-02-15 | 2022-08-18 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
-
2019
- 2019-12-19 MX MX2021007179A patent/MX2021007179A/es unknown
- 2019-12-19 US US16/721,079 patent/US11485736B2/en active Active
- 2019-12-19 AU AU2019405925A patent/AU2019405925A1/en active Pending
- 2019-12-19 BR BR112021010715A patent/BR112021010715A2/pt unknown
- 2019-12-19 KR KR1020217017482A patent/KR20210105887A/ko unknown
- 2019-12-19 CN CN201980079551.2A patent/CN113164485A/zh active Pending
- 2019-12-19 SG SG11202106232TA patent/SG11202106232TA/en unknown
- 2019-12-19 CA CA3122108A patent/CA3122108A1/en active Pending
- 2019-12-19 EP EP19897934.6A patent/EP3897652A4/en active Pending
- 2019-12-19 WO PCT/US2019/067521 patent/WO2020132269A1/en unknown
- 2019-12-19 JP JP2021531985A patent/JP2022511515A/ja active Pending
-
2021
- 2021-06-15 IL IL284050A patent/IL284050A/en unknown
- 2021-06-16 CL CL2021001575A patent/CL2021001575A1/es unknown
- 2021-07-12 CO CONC2021/0009078A patent/CO2021009078A2/es unknown
-
2022
- 2022-10-11 US US18/045,770 patent/US11787813B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2019405925A1 (en) | 2021-07-29 |
KR20210105887A (ko) | 2021-08-27 |
CL2021001575A1 (es) | 2022-06-03 |
SG11202106232TA (en) | 2021-07-29 |
US11485736B2 (en) | 2022-11-01 |
US11787813B2 (en) | 2023-10-17 |
US20210115049A1 (en) | 2021-04-22 |
TW202039501A (zh) | 2020-11-01 |
EP3897652A1 (en) | 2021-10-27 |
MX2021007179A (es) | 2021-09-28 |
JP2022511515A (ja) | 2022-01-31 |
WO2020132269A1 (en) | 2020-06-25 |
CA3122108A1 (en) | 2020-06-25 |
BR112021010715A2 (pt) | 2021-11-16 |
IL284050A (en) | 2021-08-31 |
CN113164485A (zh) | 2021-07-23 |
US20230203046A1 (en) | 2023-06-29 |
EP3897652A4 (en) | 2022-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021009078A2 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
CO2022008091A2 (es) | Inhibidores de kras g12c | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
CO2017011038A2 (es) | Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca” | |
GT201600123A (es) | Inhibidores de syk | |
CL2018002924A1 (es) | Inhibidores de bromodominios | |
CR20150264A (es) | Compuestos biciclicos de urea, tiourea, guanidina y cianoguanidina utiles para el tratamiento del dolor | |
UY36207A (es) | Inhibidores de la syk | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
CO2019012571A2 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
DOP2013000207A (es) | Derivados de piridinilo y pirazinil-metiloxi-arilo utiles como inhibidores de la tirosina cinasa del bazo (syk) | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
CL2019002527A1 (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer. | |
CL2023002223A1 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
CL2022000214A1 (es) | Inhibidores de enzimas | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
CL2023002486A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
CL2021001830A1 (es) | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa |